Plain-English translation of NCT05610865 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.
This trial is testing a new approach to healing stubborn diabetic foot ulcers using stem cells derived from autologous adipose tissue — cells harvested from your own fat. Researchers will compare four groups: standard wound care alone, platelet-rich plasma (PRP) injections alone, PRP combined with stromal vascular fraction (SVF) cells, and PRP combined with cultured stem cells. The goal is to see whether adding these cells to PRP injections can help ulcers heal faster and better than current treatments.
Diabetic foot ulcers are difficult to heal and can lead to serious complications including infection and amputation. Current standard care with dressings and off-loading works, but many ulcers heal slowly or not at all. This trial exists to see whether using a patient's own stem cells might jumpstart the healing process and offer a better option for people struggling with these wounds.
You likely qualify if…
You likely don't qualify if…
If you qualify, you will have a small fat tissue sample removed (similar to liposuction) under local or general anesthesia. Stem cells will be isolated from this tissue and mixed with platelet-rich plasma (made from your own blood) in the laboratory. You will then receive injections of the cell mixture directly into and around your foot ulcer. You'll be assigned to one of four groups: standard wound dressing alone, PRP alone, PRP with one type of stem cell, or PRP with another type of stem cell. The study will follow your healing progress over time to see which approach works best.
AI-generated summary from trial data · Jun 1, 2026 · Not medical advice
Pakistan